Cortagen
Cortagen (Ala-Glu-Asp-Pro tetrapeptide)
No human clinical trials have been conducted. All evidence comes from animal or laboratory studies.
A synthetic short peptide originally derived from a brain extract, studied in laboratory and animal research for nerve repair and brain protection. No human clinical trials have been conducted, so its safety and effectiveness in people are unknown.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
All side effect data comes exclusively from animal studies or vendor reports. No human adverse event data exists, and no FAERS match was returned. The Adriani et al. 2009 mouse study found that the optimal dose of 0.03 mg/kg produced motor stimulation without anxiety or emotional-affective disturbances, but sub-chronic treatment (5 days) with other Cortagen doses and the Cortexin reference produced anxiogenic-like effects in the elevated plus maze (DOI 10.2174/1876523800902010022). The Shabanov 2013 electrophysiology study on mollusk neurons found that Cortagen at very high concentrations (1000-10000 mcM) produced nonspecific depolarization effects described as potentially toxic, while 0.1-1000 mcM effects were weak and reversible (DOI 10.17816/rcf11217-25). The Kuznik 2008 study found no effect of Cortagen on immunity or hemostasis parameters in chickens (PMID 19432169). Vendor sites report no significant adverse effects, but this is not based on controlled human studies.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-16]